(Q34653803)

English

Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Florian Seemüller

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Anja Cerovecki

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Richard Musil

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Ansgar Klimke

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Ekkehard Haen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Rebecca Schennach

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Kai-Uwe Kühn

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Hans-Peter Volz

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Michael Riedel

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

publication date

1 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

545-572

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Neuroleptic-induced supersensitivity psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clozapine as a drug of dependence

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. The Consensus Study Group on Risperidone Dosing

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The physiology, signaling, and pharmacology of dopamine receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Structure and function of dopamine receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine receptor subtypes: beyond the D1/D2 classification

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Imaging of dopamine receptors with [123I]iodobenzamide single-photon emission-computed tomography in neuroleptic malignant syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine supersensitivity correlates with D2High states, implying many paths to psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effect of ritanserin, a 5HT2A/2C antagonist, on negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Psychopharmacology of central serotonergic systems

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Multiple serotonin receptors: clinical and experimental aspects

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A decade of progress in the discovery and development of 'atypical' antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The role of serotonin receptors in the action of atypical antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The role of 5-HT2A receptors in antipsychotic activity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The alpha7-nicotinic acetylcholine receptor and the pathology of hippocampal interneurons in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Muscarinic acetylcholine receptors as CNS drug targets

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

M1 agonists for the treatment of Alzheimer's disease. Novel properties and clinical update

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Behavioural evaluation of cholinergic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Muscarinic mechanisms of antipsychotic atypicality

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Adrenoceptors and signal transduction in neurons

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Combined alpha2 and D2/3 receptor blockade enhances cortical glutamatergic transmission and reverses cognitive impairment in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopaminergic supersensitivity after neuroleptics: Time-course and specificity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A naturalistic controlled study of relapsing schizophrenic patients with tardive dyskinesia and supersensitivity psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Therapeutic tolerance and rebound psychosis during quetiapine maintenance monotherapy in patients with schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Relapse following clozapine withdrawal: effect of neuroleptic drugs and cyproheptadine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clozapine-withdrawal catatonia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clozapine Withdrawal_Emergent Dystonias and Dyskinesias

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Unexpected dystonia while changing from clozapine to risperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Differential effects of within-day continuous vs. transient dopamine D2 receptor occupancy in the development of vacuous chewing movements (VCMs) in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Olanzapine withdrawal/discontinuation-induced hyperthermia in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Discontinuation of chronic clonidine treatment: Evidence for facilitated brain noradrenergic neurotransmission

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching between second-generation antipsychotics: why and how?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Improvement of patient compliance after switching from conventional neuroleptics to the atypical neuroleptic amisulpride

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Changes in weight and other metabolic indicators in persons with schizophrenia following a switch to aripiprazole

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A 12-week, naturalistic switch study of the efficacy and tolerability of aripiprazole in stable outpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Change in sexual dysfunction with aripiprazole: a switching or add-on study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Predictors of early worsening after switch to aripiprazole: a randomized, controlled, open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP)

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Aripiprazole in treatment-refractory schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Use of Aripiprazole in treatment resistant schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Benefits of switching women schizophrenic patients to aripiprazole: a case study and brief review of the literature

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A randomized placebo-controlled trial of asenapine for the prevention of relapse of schizophrenia after long-term treatment

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Long-term assessment of Asenapine vs. Olanzapine in patients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Short-term safety and pharmacokinetic profile of asenapine in older patients with psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivotal trials

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Olanzapine as alternative therapy for patients with haloperidol-induced extrapyramidal symptoms: results of a multicenter, collaborative trial in Latin America

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching from risperidone to olanzapine in a one-year, randomized, open-label effectiveness study of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychotics.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The impact upon extra-pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Intramuscular paliperidone palmitate

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Reduction in neuroleptic-induced movement disorders after a switch to quetiapine in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Weight decline in patients switching from olanzapine to quetiapine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Efficacy and tolerability of quetiapine in patients with schizophrenia who switched from haloperidol, olanzapine or risperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Evaluation of the feasibility of switching from immediate release quetiapine to extended release quetiapine fumarate in stable outpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching from therapy with typical antipsychotic agents to risperidone: long-term impact on patient outcome

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Improvements in stable patients with psychotic disorders switched from oral conventional antipsychotics therapy to long-acting risperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Combined treatment with quetiapine and sertindole in therapy refractory insomnia after clozapine discontinuation

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Treatment with the new antipsychotic sertindole for late-occurring undesirable movement effects

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Safety of sertindole versus risperidone in schizophrenia: principal results of the sertindole cohort prospective study (SCoP).

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Efficacy and tolerability of switching to ziprasidone from olanzapine, risperidone or haloperidol: an international, multicenter study.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching from quetiapine to ziprasidone: a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Improvement In Indices Of Health Status In Outpatients With Schizophrenia Switched To Ziprasidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching from conventional antipsychotics to ziprasidone: a randomized, open-label comparison of regimen strategies

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching among antipsychotics in everyday clinical practice: focus on ziprasidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Does switching to a new antipsychotic improve outcomes? Data from the CATIE Trial

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Antipsychotic drugs and extrapyramidal side effects in first episode psychosis: a systematic review of head-head comparisons

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Switching antipsychotic medications: general recommendations and switching to amisulpride

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Interactions between antiepileptics and second-generation antipsychotics.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Commentary on strategies for switching antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Review: no evidence to support gradual over abrupt switching of antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The crossover approach to switching antipsychotics: what is the evidence?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Asenapine: a novel psychopharmacologic agent with a unique human receptor signature

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Synthesis and structure-affinity relationship investigations of 5-heteroaryl-substituted analogues of the antipsychotic sertindole. A new class of highly selective alpha(1) adrenoceptor antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Iloperidone binding to human and rat dopamine and 5-HT receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Lurasidone: a new drug in development for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effect of sertindole on extracellular dopamine, acetylcholine, and glutamate in the medial prefrontal cortex of conscious rats: a comparison with risperidone and exploration of mechanisms involved.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Pharmacological analysis of the novel, rapid, and potent inactivation of the human 5-Hydroxytryptamine7 receptor by risperidone, 9-OH-Risperidone, and other inactivating antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Agonist, antagonist, and inverse agonist properties of antipsychotics at human recombinant 5-HT(1A) receptors expressed in HeLa cells

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Catechol O -methyltransferase val 158 -met genotype and individual variation in the brain response to amphetamine

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Hyperdopaminergic tone erodes prefrontal long-term potential via a D2 receptor-operated protein phosphatase gate

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Getting specialized: presynaptic and postsynaptic dopamine D2 receptors

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The dopamine D4 receptor: biochemical and signalling properties

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine receptor gene expression in the human medial temporal lobe

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The dopamine D4 receptors and mechanisms of antipsychotic atypicality.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine D2 and D4 receptor ligands: relation to antipsychotic action

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The serotonin1A receptor: a representative member of the serotonin receptor family

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

5-HT1A receptor expression during memory formation.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Reduced anxiety-related behaviour in transgenic mice overexpressing serotonin 1A receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Serotonin 1A receptors in memory function

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Role of cortical and striatal 5-HT1A receptors in alleviating antipsychotic-induced extrapyramidal disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of tandospirone, a 5-HT1A agonistic anxiolytic agent, on haloperidol-induced catalepsy and forebrain Fos expression in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Anticataleptic 8-OH-DPAT preferentially counteracts with haloperidol-induced Fos expression in the dorsolateral striatum and the core region of the nucleus accumbens

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Evaluation of the antibradykinetic actions of 5-HT1A agonists using the mouse pole test

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Presynaptic control of serotonin on striatal dopamine function

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Serotonin receptors: their key role in drugs to treat schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Serotonin-dopamine interaction and its relevance to schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Mechanism of Action of Atypical Antipsychotic Drugs and the Neurobiology of Schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of 5-HT(2A) and 5-HT(2C) receptor antagonists on acute and chronic dyskinetic effects induced by haloperidol in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

5-HT(6) receptor and cognition.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Serotonin receptors of type 6 (5-HT6): what can we expect from them?

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The 5-HT7 receptor and disorders of the nervous system: an overview

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The physiology of brain histamine.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Behavioural characterization and amounts of brain monoamines and their metabolites in mice lacking histamine H1 receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The role of histamine and the tuberomamillary nucleus in the nervous system

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Studies on functional roles of the histaminergic neuron system by using pharmacological agents, knockout mice and positron emission tomography.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Targeted disruption of histamine H1-receptor attenuates regulatory effects of leptin on feeding, adiposity, and UCP family in mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Mechanism of histamine-induced antidiuretic response

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Role of histamine in rodent antinociception

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of two histamine-N-methyltransferase inhibitors, SKF 91488 and BW 301 U, in rodent antinociception

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

The H1- and H2-histamine blockers chlorpheniramine and ranitidine applied to the nucleus basalis magnocellularis region modulate anxiety and reinforcement related processes

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Analysis of histamine receptors in the central thermoregulatory mechanism of Mastomys natalensis

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Interactions of recombinant human histamine H₁R, H₂R, H₃R, and H₄R receptors with 34 antidepressants and antipsychotics.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Neuronal histamine in the hypothalamus suppresses food intake in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Histamine receptors: subclasses and specific ligands

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Histamine H3 receptor-mediated depression of synaptic transmission in the dentate gyrus of the rat in vitro.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Histamine H3 receptor activation selectively inhibits dopamine D1 receptor-dependent [3H]GABA release from depolarization-stimulated slices of rat substantia nigra pars reticulata

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Characterization of histamine H3 receptors regulating acetylcholine release in rat entorhinal cortex

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Recent advances in molecular pharmacology of the histamine systems: physiology and pharmacology of histamine H3 receptor: roles in feeding regulation and therapeutic potential for metabolic disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Histamine H3-receptor inverse agonists as novel antipsychotics

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Molecular cloning and characterization of a new human histamine receptor, HH4R

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Muscarinic m1 and m2 receptor proteins in local circuit and projection neurons of the primate striatum: anatomical evidence for cholinergic modulation of glutamatergic prefronto-striatal pathways

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Association of m1 and m2 muscarinic receptor proteins with asymmetric synapses in the primate cerebral cortex: morphological evidence for cholinergic modulation of excitatory neurotransmission

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Synthesis, trafficking, and localization of muscarinic acetylcholine receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Selective expression of m2 muscarinic receptor in the parvocellular channel of the primate visual cortex

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Trafficking of the muscarinic m2 autoreceptor in cholinergic basalocortical neurons in vivo: differential regulation of plasma membrane receptor availability and intraneuronal localization in acetylcholinesterase-deficient and -inhibited mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Loss of muscarinic autoreceptor function impairs long-term depression but not long-term potentiation in the striatum.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Localization of m5 muscarinic receptor mRNA in rat brain examined by in situ hybridization histochemistry.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

A behavioral study of alpha-1b adrenergic receptor knockout mice: increased reaction to novelty and selectively reduced learning capacities

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Cerebellar norepinephrine depletion and impaired acquisition of specific locomotor tasks in rats.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Adrenergic targets for the treatment of cognitive deficits in schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dopamine and norepinephrine activity in schizophrenia. An integrative perspective

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive function

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Involvement of alpha1-adrenoceptors in the basolateral amygdala in modulation of memory storage.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Role of norepinephrine in mediating stress hormone regulation of long-term memory storage: a critical involvement of the amygdala.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Noradrenaline contractions of human prostate mediated by alpha 1A-(alpha 1c-) adrenoceptor subtype

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Quantification and distribution of alpha 1-adrenoceptor subtype mRNAs in human vas deferens: comparison with those of epididymal and pelvic portions

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Subtypes of functional alpha1- and alpha2-adrenoceptors.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Activation of the noradrenergic system facilitates an attentional shift in the rat.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Novelty seeking behavior in the rat is dependent upon the integrity of the noradrenergic system.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Substitution of a mutant alpha2a-adrenergic receptor via "hit and run" gene targeting reveals the role of this subtype in sedative, analgesic, and anesthetic-sparing responses in vivo

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha2-adrenergic control of dopamine overflow and metabolism in mouse striatum

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha2-adrenoceptors modulating neuronal serotonin release: a study in alpha2-adrenoceptor subtype-deficient mice

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clinical uses of alpha2 -adrenergic agonists

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Alpha2-adrenoceptor subtypes--unexpected functions for receptors and ligands derived from gene-targeted mouse models.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Actions of alpha-2 noradrenergic agonists on spatial working memory and blood pressure in rhesus monkeys appear to be mediated by the same receptor subtype

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Treatment with the noradrenergic alpha-2 agonist clonidine, but not diazepam, improves spatial working memory in normal young rhesus monkeys.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Cardiovascular regulation in mice lacking alpha2-adrenergic receptor subtypes b and c.

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Adjunctive alpha2-adrenoceptor blockade enhances the antipsychotic-like effect of risperidone and facilitates cortical dopaminergic and glutamatergic, NMDA receptor-mediated transmission

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Serotonergic regulation of neuronal excitability in the prefrontal cortex

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Interactions between 5-HT3 receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Effects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Clozapine withdrawal symptoms after change to sertindole in a schizophrenic patient

1 reference

https://api.crossref.org/works/10.1007%2FS40263-013-0079-5

21 January 2018

Severe and uncommon involuntary movement disorders due to psychotropic drugs.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prolonged psychotic relapse after abrupt clozapine withdrawal.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching to olanzapine after unsuccessful treatment with risperidone during the first episode of schizophrenia: an open-label trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The cerebellar norepinephrine system: inhibition, modulation, and gating.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A role for norepinephrine in stress-induced cognitive deficits: alpha-1-adrenoceptor mediation in the prefrontal cortex

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of m1-m4 muscarinic acetylcholine receptor proteins in rat hippocampus and regulation by cholinergic innervation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards a muscarinic hypothesis of schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metoclopramide-induced supersensitivity psychosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic alteration of alpha 2C-adrenoceptor expression in mice: influence on locomotor, hypothermic, and neurochemical effects of dexmedetomidine, a subtype-nonselective alpha 2-adrenoceptor agonist.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization of M(2) muscarinic acetylcholine receptor protein in cholinergic and non-cholinergic terminals in rat hippocampus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effectiveness of switching antipsychotic medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Properties and roles of the three subclasses of histamine receptors in brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching of antipsychotics to aripiprazole in the treatment of schizophrenia.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serotonergic involvement in haloperidol-induced catalepsy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

EVIDENCE FOR THE EXISTENCE OF MONOAMINE NEURONS IN THE CENTRAL NERVOUS SYSTEM. II. EXPERIMENTALLY INDUCED CHANGES IN THE INTRANEURONAL AMINE LEVELS OF BULBOSPINAL NEURON SYSTEMS.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histamine inhibits dopamine release in the mouse striatum via presynaptic H3 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The effect of sudden clozapine discontinuation on management of schizophrenic patients: A retrospective controlled study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acute effects of histamine on plasma prolactin and luteininzing hormone levels in male rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Real-life switching strategies with second-generation antipsychotics.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Introduction: the art and science of switching antipsychotic medications

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Localization of the m2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Precipitation by Yohimbine of the Withdrawal Syndromes of Clonidine, Guanfacine, and Methyldopa in the Spontaneously Hypertensive Rat

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histaminergic transmission in the mammalian brain

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of serum prolactin and sexual function after switching to aripiprazole from risperidone in schizophrenia: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching clozapine responders to olanzapine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neuronal histamine modulates feeding behavior through H1-receptor in rat hypothalamus

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-drug interactions associated with second-generation antipsychotics: considerations for clinicians and patients.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Basolateral amygdala noradrenergic influences on memory storage are mediated by an interaction between beta- and alpha1-adrenoceptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Observations on switching patients with schizophrenia to risperidone treatment. Risperidone Switching Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Withdrawal symptoms after long-term treatment with low-potency neuroleptics

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The concept of supersensitivity psychosis. The particular case of clozapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic drug mechanisms and neurotransmitter systems in schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement of oral dyskinesia after switching from aripiprazole to paliperidone: a case report

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk factors for the development of neuroleptic induced akathisia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inhibition of noradrenaline release in the rat brain cortex via presynaptic H3 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Supersensitivity psychosis in patients with schizophrenia after sudden olanzapine withdrawal

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strain-dependent effects of the histamine H₄ receptor antagonist JNJ7777120 in a murine model of acute skin inflammation

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Studies on the cardiovascular actions of central histamine H1 and H2 receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Manipulation of central nervous system histamine or histaminergic receptors (H1) affects food intake in rats

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mixed agonist-antagonist properties of clozapine at different human cloned muscarinic receptor subtypes expressed in Chinese hamster ovary cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine interaction with the M2 and M4 subtypes of muscarinic receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there a limbic system equivalent of tardive dyskinesia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Presynaptic dopamine D2 and muscarine M3 receptors inhibit excitatory and inhibitory transmission to rat subthalamic neurones in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Do central antiadrenergic actions contribute to the atypical properties of clozapine?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dehydration-induced release of vasopressin involves activation of hypothalamic histaminergic neurons

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Histaminergic neuron system: morphological features and possible functions.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emerging treatments in the management of schizophrenia - focus on sertindole

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

International Union of Pharmacology. XIII. Classification of histamine receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Beyond psychopharmacology. Psychosocial strategies for getting the best results when switching antipsychotic medications.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine withdrawal-emergent dystonias and dyskinesias: a case series

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Strategies for dosing and switching antipsychotics for optimal clinical management.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine withdrawal: serotonergic or dopaminergic mechanisms?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Conversions from clozapine to other antipsychotic drugs

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early relapse after sudden withdrawal or dose reduction of clozapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine-olanzapine: a potentially dangerous switch. A report of two cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Withdrawal dyskinesia after abrupt cessation of clozapine and benztropine

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Emergence of neuroleptic malignant syndrome while switching between risperidone and paliperidone

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Proposed strategies for successful clinical management with aripiprazole

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open labeled, randomized, switch-over study of two fixed doses (10/15mg) of aripiprazole : to evaluate its safety and efficacy in the treatment of Indian patients of schizophrenia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Muscarinic acetylcholine receptor immunoreactivity after hippocampal commissural/associational pathway lesions: evidence for multiple presynaptic receptor subtypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23821039

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S40263-013-0079-5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

release_wmc3b6s6ifdw7ha2fukx72norq

1 reference

https://api.fatcat.wiki/v0/release/wmc3b6s6ifdw7ha2fukx72norq

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23821039%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34653803&oldid=2196914392"